24

Please type a plus sign (+) inside this box -

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application	09/786,235	
Filing Date		
First Named	Diane M. Gajewezyk	
Group Art Unit		
Examiner Name		
Attorney Docket Number	1039.1120 MIS-ib	

Fee Transmittal Form Assignment Papers (for an Application) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Petition to Convert a Provisional Application Power of Attorney, Revocation Change of Correspondence Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/	Total Number of Pages in T							
Fee Transmittal Form Fee Attached Drawing(s) Tee Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Proprietary Information Proprietary Information Status Letter Drawing of Correspondence Terminal Disclaimer Defective Response Postcard Postcard	ENCLOSURES (check all that apply)							
Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Fee Attached Amendment / Response After Final Aftidavits/decta Extension of Time Required Express Abandonment Information Disclosure S Certified Copy of Priorit Document(s) Response to Missing Palacomplete Application Response to M							
SIGNATURE OF ARRUGANT ATTORNEY OR ACENT								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Michael I. Stewart (Reg. No. 24,973)	or (Reg. No							
Signature hulmed Sterns								
Date March 19, 2002	Date March							

	CERTIFICATE OF MAILING	
	lence is being deposited with the United States Postal Service wit oner for Patents, Washington, D.C. 20231 on this date:	h sufficient postage as first class mail in an
Typed or printed name		
Signature	Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

: D. Gajewezyk

Appl'n. No. : 09/786,235

I.A. Filing Date : September 3, 1999

Title : TREATMENT OF CERVICAL CANCER

Grp./A.U.

Examiner

Docket No. : 1038-1129 MS:jb

March 19, 2002

BY COURIER

The Commissioner of Patents and Trademarks, Washington, D.C. 20231, U.S.A.

Response to Notification of Defective Response

The Commissioner of Patents and Trademarks, Washington, D.C. 20231, U. S. A.

Dear Sir:

This Communication is in response to the Notification of Defective

Response.

The Notification indicates that Applicant is required to submit two

items:

(1) The Oath or Declaration of the inventors is not properly executed.

With our letter of June 28, 2001 (copy enclosed), there was submitted to the PTO a Declaration and Power of Attorney executed by all inventors, with the exception of Diane M. Gajeweczyk. A copy of the Declaration enclosed for reference.

It would appear that we omitted to forward a Declaration and Power of Attorney executed on behalf of Diane M. Gajewezyk by the other inventors. It is assumed that this is the document which is missing. Applicants are preparing a Petition under 37 CFR 1.47(a) with respect to the latter document.

(2) A Sequence Listing in computer-readable form, a Sequence Listing in paper copy and an Amendment directing its entry into the specification.

With our letter of June 28, 2001, as noted therein, there was enclosed a Sequence Listing in hard copy and computer readable forms along with a Voluntary Amendment directing entry of the Sequence Listing into the specification. It would appear that this material may have become mislaid in the PTO.

A further copy of this material is enclosed.

A copy of the Notification is enclosed. It is submitted that the defects of the response have been overcome.

Respectfully submitted

Michael I. Stewart Reg. No. 24,973

Toronto, Ontario, Canada (416) 595-1155 FAX No. (416) 595-1163

Sim & McBurney

ent and Trade-mark Agents

330 University Avenue 6th floor Toronto, Canada M5G 1Ŕ7

Telephone (416) 595-1155 Fax (416) 595-1163

MICHAEL I. STEWART ROGER T. HUGHES, Q.C. TONI POLSON ASHTON JOHN H. WOODLEY KENNETH D. MCKAY TIMOTHY M. LOWMAN STEPHEN M. LANE ARTHUR B. RENAUD STEPHEN J. PERRY Patricia A. Rae DAVID A. RUSTON L.E. TRENT HORNE Lola A. Bartoszewicz

THOMAS T. RIEDER WARREN J. GALLOWAY URSULA M. MCGUINNESS ROBERT C. LIANG **ELIZABETH VALENTINA** LESLEY M. MORRISON GEOFFREY B.C. DE KLEINE

SENIOR CONSULTANTS PETER W. MCBURNEY BRENDA L. BOARDMAN

TECHNICAL ASSISTANTS KIMBERLY A. MCMANUS, Ph.D. KAMLEH J. NICOLA, B. Sc. LL.B. WENDY M. Noss, B.A., LL.B. GREGORY W. BANKS, LL.B. COBY A. B. SCHNEIDER, B.A., LL.B.

Our ref.

lease Quote 1038-1129 MIS

Your ref.

Writer's Ext.

239

E-mail:

mistewart@sim-mcburney.com

June 28, 2001

Via Courier

The Commissioner of Patents and Trademarks **Box Missing Parts** Washington, DC 20231 U.S.A.

Dear sir:

RE: US Patent Application No. 09/786,235

Applicant: D. Gajewezyk

Title: TREATMENT OF CERVICAL CANCER

In response to the Notification of Missing Requirements under 35 U.S.C. 371, submitted herewith are:

- 1. Declaration signed by the inventor and referring to the PCT filing by number and filing date.
- 2. Cheque in the amount of the Surcharge fee.
- 3. Sequence Listing in hard copy and computer-readable forms. It is hereby stated that the hard copy and computer-readable form are the same and involve no new matter.
- 4. Voluntary Amendment directing entry of the Sequence Listing into the specification.
- 5. Copy of Notices.

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of one month of the period for filing response to the Missing Requirements on this case. We enclose our cheque in the amount of the prescribed fees.

Yours very truly,

Michael I. Stewart Reg. No. 24,973

M.I.Stewart/jb Enclosure(s)





Contriessoner for Patents, Box PUT United States Patent and Tradomark Office Washington, D.C. 2023



Date Mailed: 02/20/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- . U.S. Basic National Fee
- Priority Document
- Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):





- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

PATRICIA A BOOKER

Telephone: (703) 305-3738

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/786,235	PCT/CA99/00807	1038-1129 MIS:jb

FORM PCT/DO/EO/916 (371 Formalities Notice)